Introduction: Mucinous cystic neoplasms (MCN) are mucin-producing epithelial cell tumors of pancreas. They consist of an ovarian-type stroma expressing estrogen and progesterone receptors. Pregnancy-associated MCNs are presumed to be larger in size and more aggressive without any concrete evidence.
Objective: and Data Sources: Systematic review of published literature using PubMed and Google Scholar databases. Original articles including case reports and series published between 1970&2021 were included wherein MCN was diagnosed during pregnancy/within one-year post-partum. Thirty-three publications having 36 cases, adding one of our own patient were analyzed in this review.
Result: Median age at presentation was 32 years. Only three (9%) patients were asymptomatic. Mean size of MCN was 135 mm. Ten patients (27%) reported an increase in size during pregnancy. Most tumors involved body and tail of pancreas (60%). Distal pancreatectomy with splenectomy was the most common resection performed (57%). No foetal mortality was reported to date.
Conclusion: Pregnancy may cause a rapid increase in size of MCN. Decision-making is more complex and needs a fine balance between optimal oncological and obstetric outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjsurg.2022.11.002 | DOI Listing |
Abdom Radiol (NY)
December 2024
Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, USA.
Biliary and peribiliary cystic lesions represent a diverse group of abnormalities, often discovered incidentally during imaging for unrelated conditions. These lesions, typically asymptomatic, necessitate precise imaging modalities to characterize their nature and determine subsequent clinical actions, such as follow-up imaging, biopsy, or surgical referral. The anatomic location of these cystic lesions, whether biliary or peribiliary, influences both diagnostic and prognostic outcomes.
View Article and Find Full Text PDFPancreatology
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Background: Multiple management guidelines for intraductal papillary mucinous neoplasms (IPMNs) have been published to improve risk stratification and resource utilization. This study aims to evaluate trends in endoscopic ultrasound (EUS) use and agreement between cross-sectional imaging and EUS for specific pancreas cystic lesion (PCL) features.
Methods: This retrospective cohort study included consecutive adults undergoing EUS for suspected IPMN detected with cross-sectional imaging (CT/MRCP) between 2013 and 2015 (Cohort 1) and 2018-2020 (Cohort 2).
J Cancer Res Ther
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Mature cystic teratoma (MCT) is the most common germ cell tumor of the ovary, comprising 20% of all ovarian neoplasms. Malignant transformation (MT) is an uncommon complication and occurs in approximately 1-3% of all MCTs. The most common histological type of MT is squamous cell carcinoma.
View Article and Find Full Text PDFInt J Surg Case Rep
December 2024
Faculty of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania; Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Kilimanjaro Clinical Research Institute, Moshi, Tanzania. Electronic address:
Introduction And Importance: Ovarian atypical proliferative mucinous tumor (APMT) is a low-malignant or borderline tumor that originates from the ovary's surface epithelium. This tumor can grow to a massive size, causing abdominal distention, which can result in a variety of compression symptoms if it is not discovered early.
Case Presentation: A 23-year-old female presented with a chronic, gradually developing abdominal distention that had been persistent for a year.
Int J Urol
December 2024
Department of Urology, Keio University School of Medicine, Shinjuku-Ku, Tokyo, Japan.
Objective: Clinical trials have demonstrated the efficacy and safety of avelumab + axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC). However, information is limited regarding the activity of avelumab + axitinib in patients with non-clear cell RCC (nccRCC). In Japan, post-marketing surveillance (PMS) of patients with RCC receiving avelumab + axitinib treatment in general clinical practice was undertaken.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!